# ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

> **NCT03183141** · PHASE3 · COMPLETED · sponsor: **Seres Therapeutics, Inc.** · enrollment: 263 (actual)

## Conditions studied

- Clostridioides Difficile Infection

## Interventions

- **BIOLOGICAL:** SER-109

## Key facts

- **NCT ID:** NCT03183141
- **Lead sponsor:** Seres Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03183141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03183141, "ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03183141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*